Sarepta Therapeutics Inc (SRPT): Today's Featured Drugs Winner

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Sarepta Therapeutics ( SRPT) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day up 0.8%. By the end of trading, Sarepta Therapeutics rose $0.67 (2.3%) to $30.29 on light volume. Throughout the day, 1,142,234 shares of Sarepta Therapeutics exchanged hands as compared to its average daily volume of 1,915,000 shares. The stock ranged in a price between $29.41-$30.36 after having opened the day at $29.55 as compared to the previous trading day's close of $29.62. Other companies within the Drugs industry that increased today were: Peregrine Pharmaceuticals ( PPHM), up 47.6%, Tekmira Pharmaceuticals Corporation ( TKMR), up 29.7%, Arrowhead Research Corporation ( ARWR), up 24.5% and Tianyin Pharmaceutical ( TPI), up 17.8%.

Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA-based therapeutics for the treatment of rare and infectious diseases. Sarepta Therapeutics has a market cap of $1.1 billion and is part of the health care sector. Shares are up 39.2% year to date as of the close of trading on Tuesday. Currently there are 7 analysts that rate Sarepta Therapeutics a buy, 1 analyst rates it a sell, and 7 rate it a hold.

TheStreet Ratings rates Sarepta Therapeutics as a sell. Among the areas we feel are negative, one of the most important has been a generally disappointing historical performance in the stock itself.

On the negative front, XOMA ( XOMA), down 27.8%, Synta Pharmaceuticals ( SNTA), down 13.5%, Karyopharm Therapeutics ( KPTI), down 8.8% and China Pharma ( CPHI), down 6.5% , were all laggards within the drugs industry with Biogen Idec ( BIIB) being today's drugs industry laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

More from Markets

Jim Cramer: Schlumberger Predicted the Rise in Oil Prices

Jim Cramer: Schlumberger Predicted the Rise in Oil Prices

Jim Cramer on Zillow's New Business: Buying and Selling Homes

Jim Cramer on Zillow's New Business: Buying and Selling Homes

Jim Cramer on the Markets: It's Natural to Have Some Profit Taking

Jim Cramer on the Markets: It's Natural to Have Some Profit Taking

Video: As Trade Worries Subside, Expect a 'Relief Rally' in Stocks

Video: As Trade Worries Subside, Expect a 'Relief Rally' in Stocks

Stocks Trade Mixed Amid Progress on U.S.-China Trade; Dow Turns Lower

Stocks Trade Mixed Amid Progress on U.S.-China Trade; Dow Turns Lower